

ESMO Virtual Advanced Course on Clinical Questions in Prostate Cancer

Programme

**ESMO VIRTUAL
ADVANCED COURSE**

25-26 MARCH 2021

Co-Chairs

Karim Fizazi, France

Ravindran Kanesvaran, Singapore

ESMO VIRTUAL ADVANCED COURSE PROGRAMME CLINICAL QUESTIONS IN PROSTATE CANCER

25-26 March 2021

CO-CHAIRS: Karim Fizazi, France
Ravindran Kanesvaran, Singapore

SPEAKERS: Arun Azad, Australia
Elena Castro Marcos, Spain
Melvin Lee Kiang Chua, Singapore
Darren M.C. Poon, Hong Kong
Sue Ping Thang, Singapore

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
- To learn about state-of-the-art advances in treatment of prostate cancer
- To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+8

Thursday, 25 March 2021

- 15:00-15:05 **Welcome and course overview**
5' Karim Fizazi, FR
Ravindran Kanesvaran, SG
- 15:05-15:45 **Session 1**
State-of-the-art in prostate cancer diagnostics
- 15' PSMA based diagnostics: The future of imaging
Sue Ping Thang, SG
- 15' Biology: Clinical genomics in prostate cancer management
Elena Castro Marcos, ES
- 10' Discussion
Faculty
- 15:45-15:55 Break**
- 15:55-16:35 **Session 2**
High risk localized prostate cancer
- 15' Role of radiotherapy: Recent advances in RT modalities (*including hypofractionation, brachytherapy, SABR*)
Melvin Lee Kiang Chua, SG
- 15' High risk localized disease: Integrating drugs with local treatments
Darren M.C. Poon, HK
- 10' Discussion
Faculty
- 16:35-17:25 **Session 3**
Intermediate situation of advanced prostate cancer
- 15' Rising PSA: nmHSPC
Darren M.C. Poon, HK
- 15' Oligometastatic prostate cancer
Melvin Lee Kiang Chua, SG
- 10' M0 Castrate Resistant Prostate Cancer (CRPC): What are our latest options?
Arun Azad, AU
- 10' Discussion
Faculty

- 17:25-18:05 **Session 4**
Metastatic prostate cancer – part 1
- 15' Metastatic hormone sensitive prostate cancer: State of the art management in 2021
Ravindran Kanesvaran, SG
- 15' Metastatic CRPC: Standard of care in 2021 (*including bone targeting agents*)
Arun Azad, AU
- 10' Discussion
Faculty

Friday, 26 March 2021

- 15:00-15:25 **Session 5**
Metastatic prostate cancer – part 2
- 15' Metastatic CRPC: What's on the horizon – new treatments (PARP inhibitors, BiTE)
Karim Fizazi, FR
- 10' Discussion and summary
Karim Fizazi, FR
Ravindran Kanesvaran, SG

- 15:25-17:35 **Workshops sessions**
Three workshops sessions
10' Introduction based on clinical cases presented by speakers
30' Discussion

- Workshop 1** **Localized prostate cancer**
40' Darren M.C. Poon, HK
Melvin Lee Kiang Chua, SG

16:05-16:15 **Break**

- Workshop 2** **Intermediate advanced prostate cancer**
40' Ravindran Kanesvaran, SG
Arun Azad, AU

- Workshop 3** **Metastatic prostate cancer**
40' Karim Fizazi, FR
Elena Castro Marcos, ES

17:35-18:00 **Feedback on the workshops**

- 18:00-18:05 **Synthesis and wrap-up**
Karim Fizazi, FR
Ravindran Kanesvaran, SG